Navigation Links
Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
Date:9/13/2011

optimum dosing flexibility and efficacy.  XaraColl is easy to use and can be cut or rolled depending on the surgical setting and can be used laparoscopically.  

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm®, DermaSil™ and Liquicoll®.  Approved products based on the Company's technologies include:  Collatamp G®,  Septocoll®, Collieva®, CollaCare®, Collexa®, Zorpreva™ and, LidoColl®

Other products in development include:  CollaRx surgical Implant in phase 3 (licensed in the U.S. to Baxter Healthcare, a division of Baxter International Inc.) Cogenzia® in phase 3 development for the adjuvant treatment of infected Diabetic Foot Ulcers, and CollaGUARD®, for the prevention of surgical adhesions, which has been submitted for approval in the EU. For more information, please visit www.innocollinc.com.


'/>"/>
SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
2. Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients
3. Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
10. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)... Germany , Aug. 21, 2014  IBM (NYSE: ... Elektronen-Synchrotron ( DESY ), a leading national research center ... management and storage of massive volumes of x-ray data. ... based on IBM software defined technology can handle more ... performance and help scientists worldwide gain faster insights into ...
(Date:8/21/2014)...  Seventy-one percent of Americans believe the abuse of strong ... health and safety issue in the United States ... by Repass & Partners, a Cincinnati ... severity of the prescription medication abuse problem and the need ... health situation facing our country," Rex Repass , CEO ...
Breaking Medicine Technology:Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... Fla., Dec. 5, 2011 Hybrid Fuels, Inc., (Pink ... of its main business activities and new strategic goals.  ... a nutraceutical/pharmaceutical business venture that will focus on providing ... normally be treated or addressed with pharmaceutical drugs that ...
... Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical ... inflammation and autoimmune disorders, today announced Dr. Debra Odink ... Officer and Senior Vice President. "Over ... scientific leadership has been critical to the success of ...
Cached Medicine Technology:Hybrid Fuels, Inc. Announces New Business Strategy 2Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer 2
(Date:8/22/2014)... 22, 2014 Beat Eczema , ... can use natural methods to completely cure the eczema ... attention of Shane Michaels, prompting an investigative review. ... the skin, it can still be extremely debilitating and ... “The intense itching and pain that it causes on ...
(Date:8/22/2014)... time an oncogenic somatic mutation at amino acid 918 ... identified in small cell lung cancer (SCLC) tumors and ... produced increased intracellular signaling and cell growth. , SCLC ... 15% of all lung cancers and is strongly associated ... has been extensively examined for genomic alterations and targeted ...
(Date:8/22/2014)... Paying tuition and other related educational expenses ... for four nurse educators pursuing advanced degrees, thanks to ... Foundation for Nursing Education . This year’s recipients – ... than in 2013, thanks to these named NLN Foundation ... Marcil Endowment Funds, both donated by Kathy Mershon; the ...
(Date:8/22/2014)... August 22, 2014 Testosterone treatment ... in U.S. courts on behalf of men who ... use of prescription low testosterone therapies, Bernstein Liebhard ... claim was filed against Pfizer Inc. on July ... life-threatening heart issues due to his use of ...
(Date:8/22/2014)... Hudson County, NJ (PRWEB) August 22, 2014 ... that a leading specialist in Internal Medicine, Geriatrics, ... joined the network, CarePoint Health Medical Group. Their ... of highly skilled and experienced physicians comprise CarePoint ... doctors and practices in Hudson County, representing a ...
Breaking Medicine News(10 mins):Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... to Assure ... POWELL, Ohio, June 2 Click4Care, Inc., a ... payers,providers and patients, today announced that Cariten Healthcare, one ... subsidiary of,Covenant Health, has selected ThinkHealth for its medical ...
... Awarded Seven Gold Healthcare Advertising Marketing Awards, ... record number of over 4,400,entries, the 25th ... awards to Publicis Indianapolis and St. Vincent ... television), and marketing,work. Additionally, both entities won ...
... In a multi-site study, Oregon Health & Science University ... also known as MDX-010, works to stimulate the body,s own ... to be effective in study participants with a serious type ... and was resistant to hormonal treatment and, in some cases, ...
... (BioMedical Enterprises, Inc.),a privately held medical device company and ... launch of the OSSAnchor(TM),Grip, a nitinol implant designed to ... the first in the family of OSSAnchor(TM) nitinol soft,tissue ... Grip is a,nitinol implant with aggressive barbs on the ...
... Care Association Raising Profile of Key Issue Impacting,Texas Seniors, ... June 2 With just more than,five months until ... by Baselice Associates finds 57% of voters less likely ... she opposed increasing the amount,the state pays nursing homes ...
... Entitled, ,Ingenuity at Work, Discusses Abbott,s, Contributions to ... ABBOTT PARK, Ill., June 2 Abbott (NYSE: ... Report, "Ingenuity at Work,",which is available online at ... access to care, innovation, science,education and the environment., ...
Cached Medicine News:Health News:Click4Care Signs Award-Winning 500,000-Member Health Plan 2Health News:Publicis Indianapolis and St. Vincent Hospital Win the Gold 2Health News:OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 2Health News:OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 3Health News:BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSAnchor(TM) Grip Nitinol Soft Tissue Anchor 2Health News:Texas Eldercare Poll: 57 Percent Less Likely to Back Local Legislator if They Oppose Medicaid Rate Boost 2Health News:Texas Eldercare Poll: 57 Percent Less Likely to Back Local Legislator if They Oppose Medicaid Rate Boost 3Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 2Health News:Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care 3
The rectangular large-field lens of the 2631 are ideal for reading and writing....
The Multi-Purpose Stand Magnifier is the most versatile stand magnifier. The stand has multiple configurations allowing for all situations where hands-free magnification is needed....
Thinprofile design eyelid implants....
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Medicine Products: